Pyxis Oncology, Inc. (PYXS)Healthcare | Biotechnology | Boston, United States | NasdaqGS
1.66 USD
-0.04
(-2.353%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.71 +0.05 (3.169%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:28 p.m. EDT
PYXS is currently in a volatile and uncertain environment, with mixed signals from both the options market and recent price movements. The recent price history shows a range-bound pattern with some upward momentum, but the fundamentals are weak with negative earnings and a high debt-to-equity ratio. The lack of dividend history and the high short ratio suggest caution. While there is potential for a short-term rally, the long-term outlook is bleak, and investors should be wary of the high risk associated with this stock. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.072911 |
| AutoETS | 0.097062 |
| AutoTheta | 0.104145 |
| AutoARIMA | 0.107520 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 78% |
| H-stat | 1.06 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.807 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 34.963 |
| Revenue per Share | 0.223 |
| Market Cap | 104,299,872 |
| Forward P/E | -1.27 |
| Beta | 1.42 |
| Website | https://www.pyxisoncology.com |
As of April 11, 2026, 1:28 p.m. EDT: Options speculators are showing mixed signals. The calls have higher open interest and volume on the higher strike prices, indicating potential bullish sentiment for higher prices. However, the puts also show significant activity, particularly on the higher strike prices, which might suggest some bearish sentiment or hedging against downside risk. The overall volatility and the presence of both bullish and bearish options positions suggest uncertainty about the short-term direction of PYXS.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5660378 |
| Address1 | 321 Harrison Avenue |
| Address2 | 11th Floor, Suite 1 |
| All Time High | 19.0 |
| All Time Low | 0.833 |
| Ask | 2.12 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 413,220 |
| Average Daily Volume3 Month | 408,622 |
| Average Volume | 408,622 |
| Average Volume10Days | 413,220 |
| Beta | 1.419 |
| Bid | 1.26 |
| Bid Size | 2 |
| Book Value | 0.852 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.66 |
| Current Ratio | 3.412 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.75 |
| Day Low | 1.65 |
| Debt To Equity | 34.963 |
| Display Name | Pyxis Oncology |
| Earnings Timestamp | 1,774,269,000 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -77,334,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.726 |
| Enterprise To Revenue | 4.049 |
| Enterprise Value | 56,115,868 |
| Eps Current Year | -1.2775 |
| Eps Forward | -1.3025 |
| Eps Trailing Twelve Months | -1.28 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4856 |
| Fifty Day Average Change | 0.17439997 |
| Fifty Day Average Change Percent | 0.11739363 |
| Fifty Two Week Change Percent | 56.60378 |
| Fifty Two Week High | 5.55 |
| Fifty Two Week High Change | -3.8900003 |
| Fifty Two Week High Change Percent | -0.7009009 |
| Fifty Two Week Low | 0.92 |
| Fifty Two Week Low Change | 0.73999995 |
| Fifty Two Week Low Change Percent | 0.80434775 |
| Fifty Two Week Range | 0.92 - 5.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,699,800,000 |
| Float Shares | 40,395,465 |
| Forward Eps | -1.3025 |
| Forward P E | -1.2744721 |
| Free Cashflow | -31,380,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.82768 |
| Gross Profits | 11,470,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22457 |
| Held Percent Institutions | 0.37595 |
| Implied Shares Outstanding | 62,831,246 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. |
| Long Name | Pyxis Oncology, Inc. |
| Market | us_market |
| Market Cap | 104,299,872 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_629268721 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -79,621,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 104,299,868 |
| Number Of Analyst Opinions | 8 |
| Open | 1.72 |
| Operating Cashflow | -63,502,000 |
| Operating Margins | -1.59476 |
| Payout Ratio | 0.0 |
| Phone | 617 453 3596 |
| Post Market Change | 0.052600026 |
| Post Market Change Percent | 3.1686764 |
| Post Market Price | 1.7126 |
| Post Market Time | 1,776,470,390 |
| Previous Close | 1.7 |
| Price Eps Current Year | -1.2994128 |
| Price Hint | 4 |
| Price To Book | 1.9483567 |
| Price To Sales Trailing12 Months | 7.5263295 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.197 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.0400001 |
| Regular Market Change Percent | -2.35295 |
| Regular Market Day High | 1.75 |
| Regular Market Day Low | 1.65 |
| Regular Market Day Range | 1.65 - 1.75 |
| Regular Market Open | 1.72 |
| Regular Market Previous Close | 1.7 |
| Regular Market Price | 1.66 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 327,265 |
| Return On Assets | -0.41136003 |
| Return On Equity | -0.91435 |
| Revenue Per Share | 0.223 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,831,246 |
| Shares Percent Shares Out | 0.0424 |
| Shares Short | 2,660,931 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,525,155 |
| Short Name | Pyxis Oncology, Inc. |
| Short Percent Of Float | 0.0511 |
| Short Ratio | 7.69 |
| Source Interval | 15 |
| State | MA |
| Symbol | PYXS |
| Target High Price | 9.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.875 |
| Target Median Price | 7.0 |
| Total Cash | 66,857,000 |
| Total Cash Per Share | 1.064 |
| Total Debt | 18,673,000 |
| Total Revenue | 13,858,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.13945 |
| Two Hundred Day Average Change | -0.4794501 |
| Two Hundred Day Average Change Percent | -0.2240997 |
| Type Disp | Equity |
| Volume | 327,265 |
| Website | https://www.pyxisoncology.com |
| Zip | 2,118 |